Compare Medpace Holdings Inc (MEDP) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Zillow Group Inc Class C — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Zillow Group Inc Class C trades at $29.01 (market cap $6.59B). The key difference: Medpace Holdings Inc is far larger — about 2.6× Zillow Group Inc Class C's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Zillow Group Inc Class C for 38 Days on average.
| MEDP | Z | |
|---|---|---|
Market Cap | $16.82B | $6.59B |
Volume | 223,093 | 9,134,294 |
Sector | Health | Media |
52-Week High | $630.19 | $78.04 |
52-Week Low | $393.42 | $27.13 |
Typical Hold Time | 14 Days | 38 Days |
Enterprise Value | $16.44B | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Zillow Group (Z) trades at $29.01, up 6.34% in the past 24 hours, showing strong momentum despite mixed technical signals. The company demonstrates improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability with $23M net income. Recent earnings show two consecutive beats against expectations, though the stock faces headwinds from elevated mortgage rates and housing market volatility.
The outlook remains cautiously optimistic with analyst consensus price target of $60.33 suggesting significant upside potential. However, investors face risks from housing market sensitivity to interest rates and competitive pressures. The company's transition to an integrated transaction platform and AI integration present growth opportunities, but execution risks and market conditions warrant careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
